公平贸易委员会阻止了Alcon的1.5B交易,以收购LENSAR,结束合并。 FTC blocks Alcon’s $1.5B deal to buy LENSAR, ending merger.

LENSAR, Inc.和Alcon Research, LLC在联邦贸易委员会的反对下终止了合并协议,联邦贸易委员会对此表示关切,担心对眼睛保健市场的潜在竞争影响。 LENSAR, Inc. and Alcon Research, LLC have terminated their merger agreement following opposition from the Federal Trade Commission, which raised concerns about potential competition impacts in the eye care market. 这些公司于2026年3月16日确认了终止合同,终止了Alcon收购LENSAR的计划,LENSAR是先进的白内障外科技术的开发者。 The companies confirmed the termination on March 16, 2026, ending plans for Alcon to acquire LENSAR, a developer of advanced cataract surgery technology. 没有透露关于公平贸易委员会反对的理由的进一步详情。 No further details on the reasons for the FTC’s opposition were disclosed.